Masitinib treatment for ALS led to 42% of patients in a clinical trial surviving five years, nearly double historical rates, ...

PRESS RELEASEAB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH ...

Masitinib is an experimental oral therapy for ALS that's aimed at slowing disease progression. AB Science secured insurance ...

AB SCIENCE WILL HOLD A WEBCAST ON THIS RESEARCH PROGRAM ON THURSDAY, NOVEMBER 30, 2023, FROM 3PM TO 4PM CET AB Science SA (Euronext - FR0010557264 - AB) announces today that a new clinical development ...

AB Science SA (Euronext - FR0010557264 - AB) today provides an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment ...

European Medicines Agency accepts Marketing Authorization Application for conditional approval of masitinib in the treatment of pancreatic cancer. PARIS--(BUSINESS WIRE)-- Regulatory News: AB Science ...

The investigational drug, masitinib (AB Science), which has a completely new mechanism of action for multiple sclerosis (MS), has shown a positive result in slowing disability in patients with primary ...

In new research published in the open-access, peer-reviewed scientific journal PLoS ONE, Dr Patrice Dubreuil and colleagues characterise the pharmacological profile of masitinib (AB1010), a novel ...

Please provide your email address to receive an email when new articles are posted on . The addition of masitinib to gemcitabine significantly prolonged OS in patients with advanced pancreatic cancer ...

Figure 1 shows the trial profile. Thirty-five patients were recruited and randomized from six centers in France, corresponding to an intent-to-treat (ITT) population of 27 patients in the masitinib ...

The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids. After careful ...

Scientists have characterized the pharmacological profile of masitinib, a novel tyrosine kinase inhibitor that targets the stem cell factor, PDGFR and Lyn. Masitinib is the active pharmacological ...